Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as P529
Palomid 529 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Palomid 529 | DRUG | comparison of different dosages of drug |
Inclusion Criteria: * Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye. * Subfoveal choroidal neovascularization (CNV) due to AMD * Total area of the lesion (in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
Palomid 529 is an investigational small molecule developed by CervoMed Inc. (ticker CRVO) for age-related macular degeneration, an eye condition in the ophthalmology therapeutic area. It is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway and has been studied in a Phase 1 clinical trial.
Palomid 529 has been studied for advanced neovascular age-related macular degeneration, the wet form of AMD in which abnormal blood vessels grow beneath the retina. Its only recorded clinical trial enrolled patients aged 50 years and older with this condition in the United States. It remains investigational and is not an approved treatment.
Palomid 529 targets MTOR, acting as an inhibitor. It is described as a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway, a signaling route involved in cell growth and blood vessel formation. This mechanism is the basis for its study in neovascular age-related macular degeneration.
Palomid 529 is being developed by CervoMed Inc., which trades under the ticker CRVO. The company is the sponsor associated with the drug's clinical development in ophthalmology, specifically for age-related macular degeneration.
Palomid 529 is in Phase 1 clinical development. Its single recorded trial, NCT01033721, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
Palomid 529 has been evaluated in one clinical trial, NCT01033721, titled a Phase I study of Palomid 529, a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway, for advanced neovascular age-related macular degeneration. The trial enrolled 13 participants in the United States, was uncontrolled, and has been completed.